Millie Ray

Millie Ray is a principal on the investment team at The Column Group, where she joined in 2017. At The Column Group, Millie is active in all elements of company formation: sourcing new ideas, recruiting key scientific talent and founders, developing scientific, business and operating plans, and taking on interim scientific and operational roles. Previously, Millie helped develop and launch Foghorn Therapeutics, where she joined full-time working in business development and scientific strategy.

Millie is passionate about translating science to give back to the global community. During the 2014 Ebola outbreak, Millie traveled to West Africa to establish one of the first onsite next-generation sequencers for Ebola viral surveillance, via Harvard University and the Broad Institute. She also traveled to Kenya with Seeding Labs and Harvard University to facilitate the transfer of surplus lab equipment to universities adopting research. Concurrently, Millie completed her doctoral studies on the effects of long non-coding RNAs on chromatin regulation. Previously, she studied epigenetic regulation in embryonic stem cells.

Millie holds an S.B. in Mathematics and an S.B. in Biology from the Massachusetts Institute of Technology. She received her Ph.D. in Genetics and Genomics from Harvard University.

Millie also serves as a director on the board of Hexagon Bio.